Monte Rosa Therapeutics, Inc. 8-K

What Happened

• Monte Rosa Therapeutics, Inc. (GLUE) filed an 8-K on January 7, 2026 announcing it has terminated the at-the-market (ATM) prospectus that was part of its Form S-3 registration statement related to its Open Market Sale Agreement with Jefferies LLC. As a result, the company will not make any sales of common stock under that Sales Agreement unless and until a new prospectus, prospectus supplement or registration statement is filed. The Sales Agreement itself remains in effect.

Key Details

• The Open Market Sale Agreement was originally dated July 1, 2022 and was amended March 20, 2025; Jefferies LLC is the sales agent.
• As of January 7, 2026, Monte Rosa has issued and sold 2,955,082 shares of common stock under the Sales Agreement for aggregate net proceeds of $24.2 million.
• Termination applies only to the ATM prospectus portion; the Sales Agreement is otherwise still in force and could resume once the company files a new prospectus or registration statement.

Why It Matters

• For investors, this means Monte Rosa temporarily cannot use the ATM program to sell additional shares into the market to raise capital until it re-files the necessary prospectus or registration materials.
• That limits an established, flexible source of near-term equity financing (and potential dilution) until the prospectus is restored, while the company retains the contractual ability to resume ATM sales once filings are completed.
• The filing is procedural and factual — it does not disclose new operational results or management changes.